Geode Capital Management
ZBIO

Geode Capital Management’s Zenas BioPharma ZBIO Stock Holding History

Geode Capital Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.4M Buy
882,654
+226,869
+35% +$4.51M ﹤0.01% 2090
2026
Q1 		$12.8M Buy
655,785
+67,392
+11% +$1.51M ﹤0.01% 2238
2025
Q4 		$21.4M Buy
588,393
+118,358
+25% +$3.89M ﹤0.01% 1963
2025
Q3 		$10.4M Buy
470,035
+96,418
+26% +$1.57M ﹤0.01% 2393
2025
Q2 		$3.62M Buy
373,617
+16,461
+5% +$160K ﹤0.01% 2894
2025
Q1 		$2.82M Buy
357,156
+8,396
+2% +$65.7K ﹤0.01% 2919
2024
Q4 		$2.86M Buy
348,760
+323,903
+1,303% +$5.05M ﹤0.01% 3009
2024
Q3 		$421K Buy
+24,857
New +$447K ﹤0.01% 3658

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Geode Capital Management's ZBIO Position: Q2 2026 in Review

Geode Capital Management increased its Zenas BioPharma (ZBIO) stake by 35% in Q2 2026, buying an estimated $4.51M and bringing the position to 882,654 shares worth $22.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2090.

Geode Capital Management first reported a position in ZBIO in Q3 2024 and has held it in 8 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Geode Capital Management held 882,654 shares of Zenas BioPharma worth $22.4M as of Q2 2026.
  • Geode Capital Management bought 226,869 Zenas BioPharma shares in Q2 2026, an estimated $4.51M.
  • Zenas BioPharma made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2090 holding.
  • Geode Capital Management first reported a position in Zenas BioPharma in Q3 2024 and has held it in 8 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.